Kenya has begun rolling out Lenacapavir (or LenyCapavir), a groundbreaking, long-acting injectable drug for HIV prevention, becoming one of the first African nations to do so. Administered twice-yearly, it offers over 99.9% protection, significantly improving compliance over daily pills. Initial doses are being distributed to high-risk groups in 15 counties starting early 2026
